The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial

Article English OPEN
Scanlon, Peter H ; Loftus, J ; Starita, C. ; Stratton, I M (2015)
  • Publisher: Wiley
  • Journal: Diabetic Medicine, volume 32, issue 1, pages 97-101 (issn: 0742-3071, eissn: 1464-5491)
  • Related identifiers: doi: 10.1111/dme.12593, pmc: PMC4307641
  • Subject: RC0254 | RE | Research Articles
    mesheuropmc: eye diseases | genetic structures

Aims\ud \ud \ud To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema.\ud \ud \ud Methods\ud \ud \ud Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25 (NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control.\ud \ud \ud Results\ud \ud \ud For all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye.\ud \ud \ud Conclusions\ud \ud \ud We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials.
  • References (18)
    18 references, page 1 of 2

    1 International Diabetes Federation. IDF Diabetes Atlas, 2013. Available at Last accessed 16 April 2014.

    2 Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Org 2004; 82: 844-851.

    3 Keenan TD, Johnston RL, Donachie PHJ, Sparrow JM, Stratton IM, Scanlon PH. United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye (Lond) 2013; 27: 1397-1404.

    4 Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M. Diabetic retinopathy and health-related quality of life. Graefes Arch Clin Exp Ophthalmol 2009; 247: 267-272.

    5 Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008; 92: 89-92.

    6 Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118: 1107-1118.

    7 Pleil AM, Cappelleri JC, Chisholm JA, Getter CA, Lustig S, Reichel MB. An interpretation of quality of life based on binocular visual acuity in German patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45. Available at http://abstracts. Last accessed 16 April 2014.

    8 EuroQol Group. EQ-5D User Guide, 2013. Available at http:// Last accessed 16 April 2014.

    9 MVH_Group. The Measurement and Valuation of Health: Final Report on the Modelling of Valuation Tariffs. Centre for Health Economics, University of York, 1995.

    10 Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-1058.

  • Metrics
    No metrics available
Share - Bookmark